231 related articles for article (PubMed ID: 33895696)
1. Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature.
Hodroj K; Barthelemy D; Lega JC; Grenet G; Gagnieu MC; Walter T; Guitton J; Payen-Gay L
ESMO Open; 2021 Jun; 6(3):100125. PubMed ID: 33895696
[TBL] [Abstract][Full Text] [Related]
2. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
3. Complete DPYD genotyping combined with dihydropyrimidine dehydrogenase phenotyping to prevent fluoropyrimidine toxicity: A retrospective study.
De Metz C; Hennart B; Aymes E; Cren PY; Martignène N; Penel N; Barthoulot M; Carnot A
Cancer Med; 2024 Mar; 13(6):e7066. PubMed ID: 38523525
[TBL] [Abstract][Full Text] [Related]
4. Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study.
de With M; Knikman J; de Man FM; Lunenburg CATC; Henricks LM; van Kuilenburg ABP; Maring JG; van Staveren MC; de Vries N; Rosing H; Beijnen JH; Pluim D; Modak A; Imholz ALT; van Schaik RHN; Schellens JHM; Gelderblom H; Cats A; Guchelaar HJ; Mathijssen RHJ; Swen JJ; Meulendijks D
Clin Pharmacol Ther; 2022 Jul; 112(1):62-68. PubMed ID: 35397172
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency.
Pallet N; Hamdane S; Garinet S; Blons H; Zaanan A; Paillaud E; Taieb J; Laprevote O; Loriot MA; Narjoz C
Br J Cancer; 2020 Sep; 123(5):811-818. PubMed ID: 32595208
[TBL] [Abstract][Full Text] [Related]
6. DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview.
Paulsen NH; Vojdeman F; Andersen SE; Bergmann TK; Ewertz M; Plomgaard P; Hansen MR; Esbech PS; Pfeiffer P; Qvortrup C; Damkier P
Basic Clin Pharmacol Toxicol; 2022 Nov; 131(5):325-346. PubMed ID: 35997509
[TBL] [Abstract][Full Text] [Related]
7. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.
Boisdron-Celle M; Capitain O; Faroux R; Borg C; Metges JP; Galais MP; Kaassis M; Bennouna J; Bouhier-Leporrier K; Francois E; Baumgaertner I; Guerin-Meyer V; Cojocarasu O; Roemer-Becuwe C; Stampfli C; Rosenfeld L; Lecompte T; Berger V; Morel A; Gamelin E
Semin Oncol; 2017 Feb; 44(1):13-23. PubMed ID: 28395758
[TBL] [Abstract][Full Text] [Related]
8. Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio.
Sistonen J; Büchel B; Froehlich TK; Kummer D; Fontana S; Joerger M; van Kuilenburg AB; Largiadèr CR
Pharmacogenomics; 2014 Sep; 15(13):1653-66. PubMed ID: 25410891
[TBL] [Abstract][Full Text] [Related]
9. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
Ostapowicz A; Dołegowska B
Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
[TBL] [Abstract][Full Text] [Related]
10. Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency.
Etienne-Grimaldi MC; Pallet N; Boige V; Ciccolini J; Chouchana L; Barin-Le Guellec C; Zaanan A; Narjoz C; Taieb J; Thomas F; Loriot MA;
Eur J Cancer; 2023 Mar; 181():3-17. PubMed ID: 36621118
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
Meulendijks D; Henricks LM; Jacobs BAW; Aliev A; Deenen MJ; de Vries N; Rosing H; van Werkhoven E; de Boer A; Beijnen JH; Mandigers CMPW; Soesan M; Cats A; Schellens JHM
Br J Cancer; 2017 May; 116(11):1415-1424. PubMed ID: 28427087
[TBL] [Abstract][Full Text] [Related]
12. Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe.
de With M; Sadlon A; Cecchin E; Haufroid V; Thomas F; Joerger M; van Schaik RHN; Mathijssen RHJ; Largiadèr CR;
ESMO Open; 2023 Apr; 8(2):101197. PubMed ID: 36989883
[TBL] [Abstract][Full Text] [Related]
13. Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping.
Royer B; Launay M; Ciccolini J; Derain L; Parant F; Thomas F; Guitton J
ESMO Open; 2023 Jun; 8(3):101577. PubMed ID: 37267808
[TBL] [Abstract][Full Text] [Related]
14. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.
Thomas F; Hennebelle I; Delmas C; Lochon I; Dhelens C; Garnier Tixidre C; Bonadona A; Penel N; Goncalves A; Delord JP; Toulas C; Chatelut E
Clin Pharmacol Ther; 2016 Feb; 99(2):235-42. PubMed ID: 26265035
[TBL] [Abstract][Full Text] [Related]
15. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Ogura K
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
[TBL] [Abstract][Full Text] [Related]
16. Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency.
Maillard M; Launay M; Royer B; Guitton J; Gautier-Veyret E; Broutin S; Tron C; Le Louedec F; Ciccolini J; Richard D; Alarcan H; Haufroid V; Tafzi N; Schmitt A; Etienne-Grimaldi MC; Narjoz C; Thomas F;
Br J Clin Pharmacol; 2023 Feb; 89(2):762-772. PubMed ID: 36104927
[TBL] [Abstract][Full Text] [Related]
17. Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options?
Knikman JE; Gelderblom H; Beijnen JH; Cats A; Guchelaar HJ; Henricks LM
Clin Pharmacol Ther; 2021 Mar; 109(3):591-604. PubMed ID: 33020924
[TBL] [Abstract][Full Text] [Related]
18. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
Meulendijks D; Cats A; Beijnen JH; Schellens JH
Cancer Treat Rev; 2016 Nov; 50():23-34. PubMed ID: 27589829
[TBL] [Abstract][Full Text] [Related]
19. The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
Ben Fredj R; Gross E; Ben Ahmed S; Hassine H; Saguem S
Pathol Biol (Paris); 2009 Sep; 57(6):470-6. PubMed ID: 18619742
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP
Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
